Zymeworks Inc
ZYME12.450USD
-0.120-0.95%
交易中 （美東）報價延遲15分鐘
873.43M總市值
虧損本益比TTM
關於 Zymeworks Inc 公司
Zymeworks Inc. 是一家全球性生物技術公司。該公司致力於發現、開發和商業化用於治療癌症和其他嚴重疾病的多功能生物治療藥物。其互補的治療平臺和完全集成的藥物開發引擎提供了靈活性和兼容性，可以精確設計和開發差異化的基於抗體的治療候選藥物。其平臺包括 Azymetric、藥物偶聯物平臺、EFECT 和 ProTECT。其主要候選產品 zanidatamab 是一種雙特異性抗體，靶向人類表皮生長因子受體 2 (HER2) 的兩個不同域。其第二個候選產品 zanidatamab zovodotin 將 zanidatamab 的雙位抗體設計與其 ZymeLink auristatin 抗體-藥物偶聯物 (ADC) 技術相結合，由其細胞毒素（癌細胞殺傷化合物）和可裂解接頭組成。其產品線包括四種臨牀前候選藥物：ZW191、ZW171、ZW220 和 ZW251。
公司簡介
公司代碼ZYME
公司名稱Zymeworks Inc
上市日期Jun 24, 2019
CEOMr. Kenneth H. (Ken) Galbraith
員工數量280
證券類型Ordinary Share
年結日Jun 24
公司地址108 Patriot Drive, Suite A
城市MIDDLETOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編19709
電話13022748744
網址https://www.zymeworks.com/
公司代碼ZYME
上市日期Jun 24, 2019
CEOMr. Kenneth H. (Ken) Galbraith
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Troy M. Cox
Mr. Troy M. Cox
Independent Director
Independent Director
7.50K
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Neil Gallagher, M.D., Ph.D.
Dr. Neil Gallagher, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Troy M. Cox
Mr. Troy M. Cox
Independent Director
Independent Director
7.50K
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月27日 週日
更新時間: 7月27日 週日
持股股東
股東類型
持股股東
持股股東
佔比
EcoR1 Capital, LLC
30.69%
Redmile Group, LLC
6.40%
Rubric Capital Management LP
5.80%
BVF Partners L.P.
5.76%
BlackRock Institutional Trust Company, N.A.
4.54%
Other
46.81%
持股股東
持股股東
佔比
EcoR1 Capital, LLC
30.69%
Redmile Group, LLC
6.40%
Rubric Capital Management LP
5.80%
BVF Partners L.P.
5.76%
BlackRock Institutional Trust Company, N.A.
4.54%
Other
46.81%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
50.16%
Investment Advisor
25.24%
Hedge Fund
17.77%
Research Firm
5.28%
Private Equity
2.49%
Venture Capital
0.92%
Bank and Trust
0.36%
Sovereign Wealth Fund
0.27%
Pension Fund
0.26%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
381
77.02M
102.91%
+3.16M
2025Q1
400
71.70M
97.61%
-1.37M
2024Q4
389
68.69M
99.73%
-8.79M
2024Q3
388
74.13M
105.03%
-25.13M
2024Q2
387
74.77M
106.29%
-27.88M
2024Q1
389
74.54M
106.20%
-28.73M
2023Q4
388
72.09M
103.65%
-29.69M
2023Q3
376
69.54M
103.06%
-33.91M
2023Q2
364
70.30M
109.70%
-27.74M
2023Q1
340
64.28M
100.47%
-34.07M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
EcoR1 Capital, LLC
22.97M
30.69%
+5.09M
+28.44%
Jun 26, 2025
Redmile Group, LLC
4.79M
6.4%
-51.52K
-1.06%
Mar 31, 2025
Rubric Capital Management LP
4.34M
5.8%
+421.11K
+10.75%
Mar 31, 2025
BVF Partners L.P.
4.31M
5.76%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
4.54%
-93.86K
-2.69%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.30M
4.42%
-169.56K
-4.88%
Mar 31, 2025
UBS Asset Management (Switzerland)
2.24M
2.99%
+918.38K
+69.53%
Mar 31, 2025
BNP Paribas Asset Management USA, Inc.
2.20M
2.94%
+222.17K
+11.25%
Mar 31, 2025
Perceptive Advisors LLC
1.86M
2.49%
-265.35K
-12.46%
Mar 31, 2025
The Vanguard Group, Inc.
1.76M
2.35%
-718.49K
-28.98%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Tema Oncology ETF
0.86%
iShares Micro-Cap ETF
0.14%
Federated Hermes MDT Small Cap Core ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Biotechnology ETF
0.09%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.09%
SPDR S&P International Small Cap ETF
0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
0.05%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.86%
Tema Oncology ETF
佔比0.86%
iShares Micro-Cap ETF
佔比0.14%
Federated Hermes MDT Small Cap Core ETF
佔比0.1%
Invesco Nasdaq Biotechnology ETF
佔比0.1%
ProShares Ultra Nasdaq Biotechnology
佔比0.1%
iShares Biotechnology ETF
佔比0.09%
iShares MSCI USA Small-Cap Min Vol Factor ETF
佔比0.09%
SPDR S&P International Small Cap ETF
佔比0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
佔比0.05%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
